Biosimilar uptake in the US lags behind the EU
A new report suggests relatively low uptake of biosimilars in the US could be costing healthcare providers billions in lost … read more »
Irish hospitals may be offered incentives to switch to biosimilars
It has been reported that the Irish HSE is to incentivise hospitals to promote the use of biosimilars in place … read more »
Canadian provinces increase use of biosimilar drugs
National and provincial Canadian governments are increasingly employing strategies to drive use of biosimilars ahead of originator products to achieve … read more »
Generics and biosimilars to benefit from SPC manufacturing waiver
A new SPC exemption will level the playing field between EU and non-EU generic and biosimilar manufacturers, and will prevent … read more »
2019 Biosimilars Commercialisation Summit in Amsterdam
MAP BioPharma are a media partner of the Biosimilars Commercialisation Summit.The conference will cover every aspect of getting your biosimilars … read more »
Improvement of GSAV Regulations – A BPI Response
The Bundestag Health Committee is seeking to clarify the Gesetz für mehr Sicherheit in der Arzneimittelversorgung (GSAV), (Greater Security in … read more »
Canada rejects FDA naming suffixes
Canada has decided upon a naming system that will help to differentiate biological reference drugs from their biosimilars, joining the … read more »
EU nears rule change aimed at boosting exports of generics and biosimilars
The EU has pressed on with its planned regulation change which aims to level the playing field between pharmaceuticals, and … read more »
Controversy over biologic to biosimilar switching
In a public hearing within the Chamber of Deputies, Federal Deputy Mr Geraldo Resende defended the criteria that only doctors … read more »
Prescribing of generic drugs surpasses biosimilars and reference drugs
A study carried out by Progenericos (Brazilian Association of Generic Medicines Industries) has shown that generic drugs were the most … read more »
